Free tool
FAERS Monitor: Feraheme
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022180 or its brand name (Feraheme, Ferumoxytol). Reports on generic versions are filed under their own applications.
Reports
1,942
Serious
1,190
61% of reports
Hospitalization
463
Death reported
131
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea468
- nausea242
- flushing230
- back pain211
- infusion related reaction211
- hypotension205
- anaphylactic reaction185
- dizziness183
- chest discomfort175
- hypersensitivity155
- chest pain139
- unresponsive to stimuli139
- vomiting137
- hyperhidrosis110
- pruritus100
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2009 | 15 |
| 2010 | 199 |
| 2011 | 96 |
| 2012 | 75 |
| 2013 | 45 |
| 2014 | 65 |
| 2015 | 75 |
| 2016 | 101 |
| 2017 | 119 |
| 2018 | 150 |
| 2019 | 246 |
| 2020 | 176 |
| 2021 | 154 |
| 2022 | 103 |
| 2023 | 85 |
| 2024 | 86 |
| 2025 | 80 |
| 2026 | 72 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,217 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| unresponsive to stimuliSignal | 139 | 58.6 | 49.9 | 7,785 |
| anaphylactic reactionSignal | 185 | 36.4 | 31.7 | 6,326 |
| infusion related reactionSignal | 211 | 34.6 | 30.4 | 6,847 |
| flushingSignal | 230 | 24.6 | 21.7 | 5,187 |
| chest discomfortSignal | 175 | 18.5 | 16.1 | 2,895 |
| hypotensionSignal | 205 | 11.1 | 9.7 | 1,886 |
| back painSignal | 211 | 9.8 | 8.7 | 1,685 |
| hyperhidrosisSignal | 110 | 9.3 | 7.7 | 806 |
| hypersensitivitySignal | 155 | 9.1 | 7.8 | 1,111 |
| dyspnoeaSignal | 468 | 9.0 | 8.3 | 3,390 |
| chest painSignal | 139 | 8.1 | 6.9 | 870 |
| dizzinessSignal | 183 | 4.0 | 3.5 | 414 |
| nauseaSignal | 242 | 3.3 | 2.9 | 403 |
| vomitingSignal | 137 | 3.2 | 2.7 | 204 |
| pruritusSignal | 100 | 2.8 | 2.3 | 118 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.